FRANCIS MAE MAGDADARO: Open Payments
NPI 1376200337 · ANAHEIM, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,233 in 151 payments from 20 companies in 2025. Trend: 2023 $3,545 · 2024 $2,714 · 2025 $3,233
Food & beverage: $3,233
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $677 |
| Otsuka America Pharmaceutical, Inc. | 19 | $443 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $399 |
| ABBVIE INC. | 22 | $358 |
| E.R. Squibb & Sons, L.L.C. | 14 | $240 |
| Lundbeck LLC | 13 | $223 |
| Teva Pharmaceuticals USA, Inc. | 8 | $172 |
| Alkermes, Inc. | 8 | $168 |
| Janssen Pharmaceuticals, Inc | 8 | $138 |
| Noven Therapeutics, LLC | 4 | $84 |
Products named: INGREZZA, REXULTI, CAPLYTA, VRAYLAR, COBENFY, ARISTADA, INVEGA SUSTENNA, ABILIFY MAINTENA.
Industry payments across CA — which companies pay providers there.
